South Africa's health system will soon offer drugs blocking the Aids virus, the body that advises the government on HIV/Aids has said. The South African National Aids Council (Sanac) made the announcement following a meeting with the Treatment Action Campaign (TAC) - a group that has been urging the government to supply the drugs.
Equity in Health
The Common Market for Eastern and Southern Africa, Africa's major free trade bloc, plans to lobby the United States and pharmaceutical companies for the right to produce generic antiretroviral drugs, according to the group's secretary general, Reuters reports. COMESA Secretary-General Erastus Mwencha said that patent disputes in the World Trade Organisation are "robbing the region of a key weapon against AIDS," according to Reuters.
Leaders of the world's richest countries agreed at the G8 summit to provide billions of dollars to help fight AIDS in Africa but, under present trade rules, much of that cash will go to multinational pharmaceutical companies. To the disappointment of pressure groups monitoring the summit, the leaders failed to make progress on new trade rules to allow poor countries to buy cheap, generic versions of new medicines - including the drugs which arrest AIDS.
Malawi's government has issued a warning to vendors involved in the illegal sale of HIV/AIDS drugs, the Malawi Standard newspaper reported. Despite calls for their arrest, the informal businesses have maintained that these were the benefits of a liberal economy. However, the Registrar of the Pharmacies, Medicines and Poisons Board, Patrick Tembo, said: "Liberalisation doesn't mean trading in pharmaceutical drugs. It is illegal. Only registered institutions like hospitals and pharmacies are allowed to sell pharmaceutical drugs."
U.S. President George W. Bush's surprise pick of a former top executive of a major U.S. pharmaceutical company and major Republican contributor as his global AIDS co-ordinator has drawn expressions of concern and even outrage among Africa and AIDS activists.
The unregulated supply of AIDS drugs in the developing world could accelerate the development of drug-resistant HIV strains, according to an expert at the London School of Hygiene and Tropical Medicine, United Kingdom. Better regulation of private-sector providers of drugs in poor nations is needed to ensure that patients use antiretroviral drugs correctly, thereby reducing the risk that a strain of drug-resistant HIV will develop.
The Nobel Prize winning Organisation Médecins Sans Frontières (MSF) and four eminent public research institutes from around the world have joined forces to address the lack of research and development in drugs for neglected diseases. A mere 10% of global health research is devoted to diseases that account for 90% of the global disease burden.
Questions about what percentage of Africa's HIV infections are caused by dirty needles has prompted U.S. Health and Human Services Secretary Tommy Thompson -- who is also the chairman of the Global Fund to Fight AIDS, Tuberculosis and Malaria -- to order a review of all research linking HIV/AIDS and medical injections, Associated Press has reported. The review could affect how funding from the $15 billion U.S. initiative to fight HIV/AIDS in Africa and the Caribbean is distributed, AP reported.
U.N. Special Envoy for HIV/AIDS in Africa Stephen Lewis, during a speech at the Global Health Council's annual conference in Washington, D.C., said that he was "aghast" at the way in which "AIDS was deepening hunger and hunger was deepening AIDS" in Southern Africa. According to Lewis, Africa "reaps what the world sows, and with a vengeance."
The World Health Assembly, the policy-framing body that gives guidance to the World Health Organisation (WHO) on the views of member states and sets global health policy, voted to support a resolution affirming that public health interests should remain paramount when framing policy on pharmaceuticals.